Fortress Biotech, Inc. (FBIO) — Financial statements
Income statement, balance sheet, and cash flow for Fortress Biotech, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 63↑9.7% | 58↓31.8% | 85↑11.6% | 76↑10.1% | 69 | |
| Cost of Revenue | 26↑22.5% | 21↓8.8% | 23↓25.6% | 31↓4.1% | 32 | |
| Gross Profit | 38↑2.4% | 37↓40.3% | 62↑37.0% | 45↑22.5% | 37 | |
| Operating Expenses | ||||||
| R&D Expenses | 12↓79.1% | 57↓46.4% | 106↓21.4% | 135↑4.7% | 129 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 96↑9.4% | 88↓3.6% | 91↓20.0% | 114↑30.9% | 87 | |
| Other Expenses | 0.00↓100.0% | 3↓62.9% | 7 | 0.00↓100.0% | 10 | |
| Operating Expenses | 108↓26.7% | 147↓27.8% | 204↓17.9% | 249↑10.3% | 225 | |
| Total Costs & Expenses | 133↓20.6% | 168↓25.9% | 227↓18.8% | 279↑8.5% | 257 | |
| Operating Results | ||||||
| Operating Income | -70↑36.4% | -110↑22.5% | -142↑30.1% | -204↓8.0% | -189 | |
| Depreciation & Amortization | 7↑47.9% | 4↓25.6% | 6↓35.9% | 9↑37.7% | 7 | |
| EBITDA | -64↑39.1% | -104↑23.0% | -136↑29.9% | -194↓32.5% | -146 | |
| EBIT | -70↑35.6% | -109↑23.1% | -142↑30.2% | -203↓32.7% | -153 | |
| Interest & Other Income | ||||||
| Net Interest Income | -8↓5.2% | -7↑23.9% | -10↑22.3% | -12↑16.5% | -15 | |
| Interest Income | 2↓7.4% | 3↓10.7% | 3↑114.8% | 1↑115.4% | 0.65 | |
| Interest Expense | 10↑1.8% | 10↓20.7% | 13↓8.2% | 14↓10.9% | 15 | |
| Non-Operating Income | -45↓3087.9% | -1↓128.2% | -0.62↓20.7% | -0.52↑98.5% | -36 | |
| Other Income / Expenses | 37↑460.9% | -10↑10.0% | -11↓14.1% | -10↓140.9% | 24 | |
| Income Before Tax | -34↑72.2% | -121↑21.5% | -154↑28.0% | -213↓29.9% | -164 | |
| Income Tax Expense | -0.62↓298.7% | 0.31↓40.1% | 0.52↑16.0% | 0.45↓5.1% | 0.47 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -33↑72.8% | -121↑21.6% | -154↑27.9% | -214↓29.8% | -165 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 7↑114.8% | -46↑24.1% | -61↑30.0% | -87↓33.8% | -65 | |
| Bottom-Line Net Income | -2↑96.6% | -56↑18.6% | -69↑27.4% | -95↓46.2% | -65 | |
| EPS (Basic) | -0.07↑97.5% | -2.69↑68.2% | -8.47↑41.8% | -14.55↓22.8% | -11.85 | |
| EPS (Diluted) | -0.07↑97.5% | -2.69↑68.2% | -8.47↑41.8% | -14.55↓22.8% | -11.85 | |
| Weighted Average Shares | 28↑34.2% | 21↑156.2% | 8↑36.9% | 6↑8.8% | 5 | |
| Weighted Average Diluted Shares | 279↑1242.5% | 21↑156.2% | 8↑36.9% | 6↑8.8% | 5 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.